NAMS
NewAmsterdamBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Composite grade B from latest DB weights. Momentum 76.7 / Value 41.1
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +1.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
77
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $49.77
Why
Momentum77 · Δ7d +1.0
Value41 · Δ7d +0.1
SentimentN/A · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
77
52% active weight
Current posture
7d trendFlat
Δ7d
+1.0
Δ21d
+25.4
Value
41
48% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade B. Momentum 76.7 / Value 41.1
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.72B
Beta
0.07
Shares Out
113.39M
P/E (TTM) · Derived
-19.0
P/S (TTM)
107.72
P/FCF (TTM) · Derived
-25.69
Rev YoY
-98.8%
EPS YoY
-244.4%
Gross Margin
-
Op Margin
-575.8%
Net Debt
-$834.19M
Current Ratio
12.57
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology